Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat for abnormal transcranial Doppler velocities in pediatric sickle cell disease
PACTR202301655446404Phase 2Recruiting
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of etavopivat in sickle cell disease (SCD) (2 arms), sponsored by Forma Therapeutics, Inc. Started Sep 2023; status: recruiting.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202301655446404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202301655446404.